COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

SinuSurf vs. Saline Solution in Normal Subjects (SinuSurf)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02728505
Recruitment Status : Completed
First Posted : April 5, 2016
Last Update Posted : March 14, 2017
NeilMed Pharmaceuticals
Information provided by (Responsible Party):
Rakesh Chandra, Vanderbilt University Medical Center

Brief Summary:
Single-center, prospective, placebo controlled trial of tolerability and safety of low-concentration SinuSurf sinus irrigation solution in normal subjects. Forty (40) healthy subjects aged 18-65 will be enrolled in the study.

Condition or disease Intervention/treatment Phase
Rhinosinusitis Drug: SinuSurf irrigation twice daily Drug: NeilMed Sinus rinse irrigation twice daily Phase 1

Detailed Description:

Rhinosinusitis, or sinusitis, is a bacterial or fungal infection in the sinuses that results from a build-up of mucus, which causes inflammation of the sinus cavities. NeilMed SinuSurf solution is a mucoactive surfactant designed to be added to NeilMed large-volume saline irrigation solution for the purpose of improving the clearance of mucus caused by sinusitis. In vitro studies have shown that topical surfactant therapies, such as SinuSurf, have been shown as an efficacious treatment of the inflammation of the sinuses (rhinosinusitis). In particular, these therapies have been shown to have antimicrobial effects, including a decrease in numbers of bacteria when used alone and an elimination of bacteria when combined with antibiotics. To date, initial safety studies of SinuSurf in an in-vitro model have confirmed a lack of toxicity to ciliary beat frequency and also a lack of toxicity in nasal explants model.

In a comparative analysis of saline and surfactant irrigation in post-operational endoscopic endonasal surgery subjects, Farag, et al. found those receiving surfactant irrigation reported more side effects and 20% of subjects on the surfactant irrigation discontinued use compared to none receiving saline. Rohrer, et al. found that surfactants, when added to saline, cleared sinus spaces significantly better than saline alone.

A previous version of SinuSurf was on the market from 2011-2012; however, it was removed from the market due to anecdotal reports of concerns regarding pain, dryness, and temporary alteration of sense of smell. While no reports of permanent alteration of sense of smell have been received, NeilMed wishes to assess the tolerability and safety of a revised, lower-concentration formulation of SinuSurf prior to re-introduction in the market. The purpose of this trial is to assess the tolerability and potential side effect profile, specifically alterations to the sense of smell, of a revised, low-concentration sinus irrigation solution in a population of normal subjects.

Healthy participants are included in this study because SinuSurf™ is an over-the-counter (OTC) product used for symptoms rather than one particular disease, just as are saline rinses. It is an over-the-counter product. One of the main outcome measures is the impact upon the sense of smell, which is already often compromised in patients with chronic nasal/sinus disease. Thus we seek to study it in patients with normal smell who also don't have other conditions that may impact sense of smell, which would potentially confound data interpretation. The dose/concentration is under patent, but involves one squirt of the "shampoo" into 240 cc of buffered nasal saline. There is anecdotal (internet) report that patients may have temporary smell loss with and that will be criteria for patient withdrawal and possibly early study termination.

The advice that SinuSurf™ not be used more than 5 days is in order to prevent patients with medical conditions that should be evaluated by physician from deferring medical advice. These warnings are typical of over the counter products. In the present study, the product will be used under the physician's oversight. The 7 days period is chosen because it is a full "week" and is conceivably a time interval over which one would expect any changes in outcome measures from baseline.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: Tolerability and Safety of Two Weeks of Twice-Daily Low-Concentration Sinusurf Sinus Irrigation Solution vs. Saline Solution in Normal Subjects
Actual Study Start Date : April 12, 2016
Actual Primary Completion Date : January 20, 2017
Actual Study Completion Date : January 20, 2017

Arm Intervention/treatment
Active Comparator: SinuSurf irrigation twice daily
This arm is going to get low-concentration SinuSurf sinus irrigation solution, then a washout period, then standard NeilMed Sinus rinse.
Drug: SinuSurf irrigation twice daily
Drug: NeilMed Sinus rinse irrigation twice daily
Placebo Comparator: NeilMed Sinus rinse irrigation twice daily
This arm is going to get standard NeilMed Sinus rinse, then a washout period, then low-concentration SinuSurf sinus irrigation solution.
Drug: SinuSurf irrigation twice daily
Drug: NeilMed Sinus rinse irrigation twice daily

Primary Outcome Measures :
  1. Sense of smell assessed by change in UPSIT-40 score between when subjects use SinuSurf, as compared to saline control. [ Time Frame: 5 weeks ]

Secondary Outcome Measures :
  1. Tolerability [ Time Frame: 5 weeks ]
    Patient preference as reflected in patient daily diary.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Individuals aged 18-65 with no sinonasal symptoms who are normosmic (as determined by UPSIT-40) and have normal anterior rhinoscopy.

Exclusion Criteria:

  • Any symptom or sign of active nasal or sinus disease from UPSIT-40 or exam of ears and nose.
  • UPSIT-40result that is not normosmic.
  • Cystic fibrosis.
  • Immunosuppression from disease or therapy (HIV, primary immune deficiency, diabetes, renal insufficiency, organ transplant, immune suppressive drug).
  • History of previous Endoscopic Sinus Surgery or nasal surgery.
  • Not willing to use contraception or abstain from sexual relations during trial period.
  • Any woman who is currently pregnant.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02728505

Layout table for location information
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University Medical Center
NeilMed Pharmaceuticals
Layout table for investigator information
Principal Investigator: Justin Turner, MD, PhD Vanderbilt University Medical Center
Study Director: Rakesh K. Chandra, MD Vanderbilt University Medical Center
Layout table for additonal information
Responsible Party: Rakesh Chandra, Professor, Vanderbilt University Medical Center Identifier: NCT02728505    
Other Study ID Numbers: 151479
First Posted: April 5, 2016    Key Record Dates
Last Update Posted: March 14, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No